FIELD: regenerative medicine.
SUBSTANCE: invention relates to a method of producing platelet-enriched fibrin matrix. The method of producing platelet-rich fibrin matrix includes the following steps: a) obtaining platelet-rich plasma (PRP), for this purpose freshly collected stabilized blood of the patient is placed in at least one hourglass-shaped tube; then the tube(s) are centrifuged until the stabilized blood is divided into three fractions, the middle of which is a leukotrombocytic suspension, which is taken from the tube(s) with the addition of the upper fraction — blood plasma, which allows the formation of platelet-rich plasma containing at least 1 million platelets in 1 mcl of product; b) obtaining serum containing thrombin, for this, freshly collected whole blood of the same patient is placed in a test tube that does not contain filler, then the test tube is centrifuged until the blood is divided into three fractions, the upper of which is plasma, after which the test tube is left at room temperature until transition of plasma from a liquid state to a fibrin clot, which is achieved by a natural coagulation cascade, after which the serum containing the resulting thrombin is separated from the fibrin clot; c) forming a composition to obtain the final product, for which the following are added sequentially to a container of the selected shape and size: autologous platelet-rich plasma obtained in step a), autologous serum containing thrombin obtained in step b), and a solution of calcium gluconate in concentration 100 mg/ml or a solution of calcium chloride at a concentration of 100 mg/ml, while the volume ratio of the components of PRP: serum containing thrombin: solution of calcium gluconate or calcium chloride is 16:2:1–16:4:2; d) the resulting mixture is left at room temperature until a platelet-enriched fibrin clot is formed; e) the resulting platelet-enriched fibrin clot is pressed from the serum to obtain a fibrin matrix.
EFFECT: use of the invention makes it possible to obtain a platelet-enriched fibrin matrix that meets the requirements of clinical practice — the possibility of intraoperative formation of a multi-purpose, biodegradable, stimulating regenerative processes, resistant to stitching with surgical threads of a graft of the desired shape and size, which is a biologically effective autologous alternative to materials of artificial origin.
16 cl, 9 dwg, 3 tbl, 4 ex
